Tripura Slashes Cancer Drug Prices by Up to 96 Percent

Photo Courtesy: nenow

Agartala: Cancer patients in Tripura just caught a major break. The National Pharmaceutical Pricing Authority slashed prices on 137 cancer drugs, covering 543 brands and 1,364 formulations, by as much as 96.45 percent. The new rates took effect November 9. The move targets both injectable chemotherapy drugs and oral medications to help families handle steep medical bills.

Subrata Das, the Tripura Deputy Drugs Controller, said the high cost of treatment often forced people to quit therapy early. "He expressed hope that the revised prices would ease their financial difficulties and help them continue treatment." Savings are already hitting the shelves. A strip of 10 Anastrozole tablets dropped from Rs 695 to Rs 73. A 50 mg Fludarabine injection fell from Rs 14,235 to Rs 2,432, while Fulvestrant injections plummeted from over Rs 26,000 to Rs 5,491.

Retailers must comply. Das ordered all pharmacies to dump old pricing, even for stock bought before the November 9 cutoff. The Drugs Control Administration and medical superintendents are now running awareness drives at sites like ILS Hospitals and GB Cancer Hospital. Officials are pushing the Pharma Sahi app, which helps shoppers verify official prices before they pay. Any store caught overcharging will face scrutiny. Patients should report price gouging to the state authorities immediately.

Disclaimer: The views and facts expressed here are solely those of the independent citizen journalist, researcher, and others, who assumes full responsibility for the content's accuracy and legality. Any third-party media (images, videos, or audio) used belongs to its respective owners and is shared strictly for reporting, criticism, or review under the "Fair Dealing" provisions of Section 52 of the Copyright Act, 1957 (India). NEWire.in does not claim ownership over such material and reserves the right to review, moderate, or remove content at its sole discretion upon receiving valid legal concerns or grievances.

Comments
Please login to comment.